Sanofi India Ltd vs Zenith Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3402 as of 05 May 15:30 . The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 5 quarters. This represents a CAGR of -100.00% The p/e ratio of Zenith Drugs Ltd changed from 11.2 to 11.2 over 1 quarters. This represents a CAGR of 0.00% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00% The market cap of Zenith Drugs Ltd changed from ₹ 107.52 crore to ₹ 107.52 crore over 1 quarters. This represents a CAGR of 0.00% The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Zenith Drugs Ltd changed from 8.99 % to 0 % over 2 quarters. This represents a CAGR of -100.00% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Zenith Drugs Ltd

Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior.
Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior. Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore.
With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company is mainly engaged in the business of manufacturing and Trading of Medicines.

FAQs for the comparison of Sanofi India Ltd and Zenith Drugs Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Zenith Drugs Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Zenith Drugs Ltd is 77 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Zenith Drugs Ltd?

The stock performance of Sanofi India Ltd and Zenith Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Zenith Drugs Ltd?

As of May 5, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Zenith Drugs Ltd stock price is INR ₹45.35.

How do dividend payouts of Sanofi India Ltd and Zenith Drugs Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Zenith Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.